We are live on ! Find out more
APVO icon

Aptevo Therapeutics
APVO

1 hedge funds and large institutions have $107M invested in Aptevo Therapeutics in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

2,034% more capital invested

Capital invested by funds: $5M → $107M (+$102M)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.02%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$48.7M

Top Sellers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
-$412K
2
GCP
GSA Capital Partners
United Kingdom
-$308K
3
WVP
Worth Venture Partners
New Jersey
-$210K
4
WG
Winton Group
United Kingdom
-$89K
5
FFA
Founders Financial Alliance
North Carolina
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
Tang Capital Management
California
$64.5M +$48.7M +3 New
RI
2
RTW Investments
New York
$10.6M – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$9.32M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$5.52M – – –
Two Sigma Investments
5
Two Sigma Investments
New York
$2.56M – – –
BlackRock
6
BlackRock
New York
$2.13M – – –
GTC
7
Ghost Tree Capital
New York
$1.83M – – –
Alyeska Investment Group
8
Alyeska Investment Group
Illinois
$1.82M – – –
AFM
9
Anson Funds Management
Texas
$1.67M – – –
Bank of Montreal
10
Bank of Montreal
Ontario, Canada
$1.14M – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.03M – – –
SCM
12
Stonepine Capital Management
Oregon
$670K – – –
Two Sigma Advisers
13
Two Sigma Advisers
New York
$568K – – –
DTL
14
Dynamic Technology Lab
Singapore
$484K – – –
BFM
15
Boothbay Fund Management
New York
$421K – – –
SSA
16
Schonfeld Strategic Advisors
New York
$407K – – –
Northern Trust
17
Northern Trust
Illinois
$319K – – –
PVI
18
Pura Vida Investments
New York
$301K – – –
SFI
19
Susquehanna Fundamental Investments
Pennsylvania
$235K – – –
T. Rowe Price Associates
20
T. Rowe Price Associates
Maryland
$231K – – –
Millennium Management
21
Millennium Management
New York
$228K – – –
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$202K – – –
Bank of America
23
Bank of America
North Carolina
$191K – – –
Morgan Stanley
24
Morgan Stanley
New York
$119K – – –
Acadian Asset Management
25
Acadian Asset Management
Massachusetts
$113K – – –
1
2

APVO Hedge Fund Activity: Q4 2020 in Review

1 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q4 2020, worth a combined $107M — up 2,034% from $5M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new APVO positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $48.7M. The largest seller was Credit Suisse, cutting an estimated $412K.

  • 1 institutional investor held Aptevo Therapeutics (APVO) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $107M of Aptevo Therapeutics stock for Q4 2020, up 2,034% quarter-over-quarter.
  • 1 fund opened new Aptevo Therapeutics positions in Q4 2020 and 0 closed out, a net change of +1 holder.
  • The largest Aptevo Therapeutics buyer in Q4 2020 was Tang Capital Management, an estimated $48.7M added.
  • The largest Aptevo Therapeutics seller in Q4 2020 was Credit Suisse, an estimated $412K sold.

Based on aggregated 13F filings for Q4 2020.